BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$4.43 USD
-0.07 (-1.56%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $4.44 +0.01 (0.23%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Income Statements
Fiscal Year end for BioCryst Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 331 | 271 | 157 | 18 | 49 |
Cost Of Goods | 4 | 6 | 7 | 2 | 4 |
Gross Profit | 327 | 264 | 150 | 16 | 45 |
Selling & Adminstrative & Depr. & Amort Expenses | 431 | 413 | 328 | 191 | 145 |
Income After Depreciation & Amortization | -104 | -148 | -178 | -175 | -99 |
Non-Operating Income | -14 | 3 | 55 | 6 | 2 |
Interest Expense | 108 | 99 | 59 | 15 | 12 |
Pretax Income | -226 | -244 | -182 | -183 | -109 |
Income Taxes | 0 | 3 | 2 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -227 | -247 | -184 | -183 | -109 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -227 | -247 | -184 | -183 | -109 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -112 | -149 | -177 | -171 | -97 |
Depreciation & Amortization (Cash Flow) | -9 | 0 | 1 | 3 | 2 |
Income After Depreciation & Amortization | -104 | -148 | -178 | -175 | -99 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 192.20 | 185.91 | 179.12 | 167.27 | 115.60 |
Diluted EPS Before Non-Recurring Items | -1.00 | -1.33 | -1.34 | -1.09 | -0.94 |
Diluted Net EPS (GAAP) | -1.18 | -1.33 | -1.03 | -1.09 | -0.94 |
Fiscal Year end for BioCryst Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 93.40 | 86.74 | 82.49 | 68.78 |
Cost Of Goods | NA | 1.56 | 1.10 | 0.89 | 0.93 |
Gross Profit | NA | 91.84 | 85.64 | 81.60 | 67.85 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 134.53 | 97.57 | 102.30 | 96.25 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -42.69 | -11.93 | -20.70 | -28.40 |
Non-Operating Income | NA | 4.09 | 3.45 | -24.97 | 3.15 |
Interest Expense | NA | 24.58 | 27.35 | 28.92 | 27.40 |
Pretax Income | NA | -63.16 | -35.82 | -74.59 | -52.66 |
Income Taxes | NA | -1.43 | 0.33 | 0.74 | 0.67 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -61.73 | -36.15 | -75.33 | -53.33 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -61.73 | -36.15 | -75.33 | -53.33 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 201.41 | 189.64 | 189.12 | 188.51 |
Diluted EPS Before Non-Recurring Items | NA | -0.28 | -0.19 | -0.24 | -0.28 |
Diluted Net EPS (GAAP) | NA | -0.31 | -0.19 | -0.40 | -0.28 |